Table 2 The comparison of tumor responses in two groups.

From: The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study

 

All patients (N = 92)

Experimental group

Control group

χ2

P value

PR

34 (36.9%)

20 (46.5%)

14 (28.6%)

3.164

0.075

CR

7 (7.6%)

4 (9.3%)

3 (6.1%)

0.329

0.702

SD

21 (22.8%)

9 (20.9%)

12 (24.5%)

0.165

0.685

PD

30 (32.63%)

10 (23.3%)

20 (40.8%)

3.214

0.073

ORR

41 (44.6%)

24 (55.8%)

17 (34.7%)

4.135

0.042

DCR

62 (67.4%)

33 (76.7%)

29 (59.2%)

3.214

0.073

  1. Data are presented as n (%, 95% CI) or n (%). CR: Complete response, PR: partial response, SD: stable disease, PD: progressive disease, ORR: object response rate, DCR: disease control rate. Significant values are in bold.
Back to article page